Equities Research Analysts’ updated eps estimates for Wednesday, May 22nd:

BioSig Technologies (NASDAQ:BSGM) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. “

Bank7 (NASDAQ:BSVN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Bank7 Corp. is the bank holding company for Bank7, operates as a community bank. It accepts deposits and makes loans, as well as provides card facilities, investments, certification of deposits, wealth management and online banking services. Bank7 Corp. is headquartered in Oklahoma City. “

Burberry Group (OTCMKTS:BURBY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Burberry Group plc is engaged in the designing, sourcing, manufacturing and marketing of luxury clothing and non-apparel accessories. The Company’s products include outerwear, fragrance and beauty products, eyewear, watches, trench coats, small leather goods, handbags, totes and mufflers, scarves, shoes, belts and jewellery. It sells through a diversified network of retail, digital, wholesale and licensing channels worldwide. Burberry Group plc is headquartered in London, the United Kingdom. “

Camtek (NASDAQ:CAMT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Camtek Ltd., designs, develops, manufactures, and markets automatic optical inspection systems and related products. Camtek’s automatic inspection systems are used to enhance both production processes and yield for manufacturers in the printed circuit board industry, the high density interconnect substrate industry and the semiconductor manufacturing and packaging industry. “

Catabasis Pharmaceuticals (NASDAQ:CATB) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

CB Financial Services (NASDAQ:CBFV) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CB Financial Services, Inc. is the bank holding company for Community Bank, a chartered commercial bank. The Bank’s services include personal banking and business banking. It offers checking, loan accounts, individual retirement accounts, wealth management, certificates of deposit, recorder check, business checking accounts, business loans, cash management and re-order check. The Bank offers other services, including merchant services, financial and wealth management, wire transfers, credit card, ATM, and online banking services. It serves business owners, non-profit groups, government agencies, school administrators, and individual personal account holders in Pennsylvania. CB Financial Services, Inc. is based in Carmichaels, Pennsylvania. “

CBTX (NASDAQ:CBTX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CBTX, Inc. is a bank holding company. It provides personal and commercial banking, real estate loans, and investment services as well as offers deposits, debit and credit cards, cash management, treasury, and online banking services. CBTX, Inc. is based in TX, United States. “

Cidara Therapeutics (NASDAQ:CDTX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $2.25 price target on the stock. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “

Chaparral Energy (NYSE:CHAP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Chaparral Energy, Inc. engages in the oil and natural gas exploration and production. It focuses on deposits of Stack, Meramec and Osage, Oswego, and Woodford located in Oklahoma and the Texas Panhandle. Chaparral Energy, Inc. is headquartered in Oklahoma City, OK. “

Chesapeake Lodging Trust (NYSE:CHSP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $34.00 target price on the stock. According to Zacks, “Chesapeake Lodging Trust is a real estate investment trust. It is a self-advised hotel investment company focused on investments in upper upscale hotels in business, airport, convention markets, and select-service hotels in urban settings or locations in the United States. “

Infineon Technologies (ETR:IFXA) was given a €21.00 ($24.42) price target by analysts at JPMorgan Chase & Co.. The firm currently has a buy rating on the stock.

Receive News & Ratings for BioSig Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.